Oral paricalcitol reduces the prevalence of posttransplant hyperparathyroidism: Results of an open label randomized trial

American Journal of Transplantation

Volumn 13, Issue 6, 2013, Pages 1576-1585

  Amer, H ^a   Griffin, M D ^b   Stegall, M D ^a   Cosio, F G ^a   Park, W D ^a   Kremers, W K ^a   Heilman, R L ^c   Mazur, M J ^c   Hamawi, K ^c   Larson, T S ^a   Kumar, R ^a  

^a MAYO CLINIC   (United States)

^b NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^c MAYO CLINIC   (United States)

Author keywords

Bone disease; hyperparathyroidism; kidney transplant; paricalcitol; vitamin D receptor agonist

Indexed keywords

ALEMTUZUMAB; ALKALINE PHOSPHATASE BONE ISOENZYME; CALCIUM; CALCIUM CARBONATE; CIDOFOVIR; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PARATHYROID HORMONE; PARICALCITOL; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; AFIBRINOGENEMIA; ARTICLE; BACTEREMIA; BONE DENSITY; BREAST CANCER; BRONCHITIS; CALCIUM EXCRETION; CELLULITIS; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; CREATININE CLEARANCE; CYTOMEGALOVIRUS INFECTION; DEPRESSION; DIABETES MELLITUS; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FALLING; FEMALE; FEVER; FRACTURE; GASTROENTERITIS; GLOMERULUS FILTRATION RATE; GOUT; GRAFT RECIPIENT; HEADACHE; HEART INFARCTION; HERPES ZOSTER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERCALCEMIA; HYPERCALCIURIA; HYPERKALEMIA; HYPOMAGNESEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LEG PAIN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALAISE; MALE; MICTURITION; NAUSEA AND VOMITING; NEUTROPENIA; PARANOIA; PARATHYROIDECTOMY; PNEUMONIA; POLYOMAVIRUS NEPHROPATHY; POSTTRANSPLANT DIABETES MELLITUS; POSTTRANSPLANT HYPERPARATHYROIDISM; PREVALENCE; PRIORITY JOURNAL; PYELONEPHRITIS; RADICULAR PAIN; RANDOMIZED CONTROLLED TRIAL; SECONDARY HYPERPARATHYROIDISM; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; SINUSITIS; STANDING; TREATMENT OUTCOME; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION; URETER OBSTRUCTION; URINARY EXCRETION; URINARY TRACT INFECTION; UROLITHIASIS; WOUND INFECTION;

ADMINISTRATION, ORAL; BONE DENSITY CONSERVATION AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ERGOCALCIFEROLS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MINNESOTA; PREVALENCE; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84878483232     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12227     Document Type: Article

References (30)

1. Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999; 341: 1725-1730.
2. Kasiske BL, Snyder J, Matas A, Collins A., The impact of transplantation on survival with kidney failure. Clin Transpl 2000; 135-143.
3. Meier-Kriesche HU, Schold JD, Kaplan B., Long-term renal allograft survival: Have we made significant progress or is it time to rethink our analytic and therapeutic strategies ? Am J Transplant 2004; 4: 1289-1295.
4. Ojo AO., Cardiovascular complications after renal transplantation and their prevention. Transplantation 2006; 82: 603-611.
5. Snyder JJ, Israni AK, Peng Y, Zhang L, Simon TA, Kasiske BL., Rates of first infection following kidney transplant in the United States. Kidney Int 2009; 75: 317-326.
6. Webster AC, Craig JC, Simpson JM, Jones MP, Chapman JR., Identifying high risk groups and quantifying absolute risk of cancer after kidney transplantation: A cohort study of 15,183 recipients. Am J Transplant 2007; 7: 2140-2151.
7. Zhang R, Alper B, Simon E, Florman S, Slakey D., Management of metabolic bone disease in kidney transplant recipients. Am J Med Sci 2008; 335: 120-125.
8. Heaf J, Tvedegaard E, Kanstrup IL, Fogh-Andersen N., Hyperparathyroidism and long-term bone loss after renal transplantation. Clin Transplant 2003; 17: 268-274.
9. Koch Nogueira PC, David L, Cochat P., Evolution of secondary hyperparathyroidism after renal transplantation. Pediatr Nephrol 2000; 14: 342-346.
10. Schmid T, Muller P, Spelsberg F., Parathyroidectomy after renal transplantation: A retrospective analysis of long-term outcome. Nephrol Dial Transplant 1997; 12: 2393-2396.
11. Evenepoel P, Claes K, Kuypers D, Maes B, Vanrenterghem Y., Impact of parathyroidectomy on renal graft function, blood pressure and serum lipids in kidney transplant recipients: A single centre study. Nephrol Dial Transplant 2005; 20: 1714-1720.
12. Stubbs JR, Wetmore JB., Does it matter how parathyroid hormone levels are suppressed in secondary hyperparathyroidism ? Semin Dial 2011; 24: 298-306.
13. El-Agroudy AE, El-Husseini AA, El-Sayed M, Ghoneim MA., Preventing bone loss in renal transplant recipients with vitamin D. J Am Soc Nephrol 2003; 14: 2975-2979.
14. Jeffery JR, Leslie WD, Karpinski ME, Nickerson PW, Rush DN., Prevalence and treatment of decreased bone density in renal transplant recipients: A randomized prospective trial of calcitriol versus alendronate. Transplantation 2003; 76: 1498-1502.
15. Shoji T, Shinohara K, Kimoto E, et al. Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant 2004; 19: 179-184.
16. Teng M, Wolf M, Lowrie E, et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003; 349: 446-456.
17. Wilson DM, Bergert JH, Larson TS, Liedtke RR., GFR determined by nonradiolabeled iothalamate using capillary electrophoresis. Am J Kidney Dis 1997; 30: 646-652.
18. Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006; 145: 247-254.
19. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713-723.
20. Cosio FG, Grande JP, Wadei H, Larson TS, Griffin MD, Stegall MD., Predicting subsequent decline in kidney allograft function from early surveillance biopsies. Am J Transplant 2005; 5: 2464-2472.
21. Coyne D, Acharya M, Qiu P, et al. Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am J Kidney Dis 2006; 47: 263-276.
22. Saini RK, Kaneko I, Jurutka PW, et al. 1,25-Dihydroxyvitamin D(3) regulation of fibroblast growth factor-23 expression in bone cells: Evidence for primary and secondary mechanisms modulated by leptin and interleukin-6. Calcif Tissue Int 2012.
23. Vervaet BA, Verhulst A, D'Haese PC, De Broe ME., Nephrocalcinosis: New insights into mechanisms and consequences. Nephrol Dial Transplant 2009; 24: 2030-2035.
24. Thadhani R, Appelbaum E, Pritchett Y, et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: The PRIMO randomized controlled trial. JAMA 2012; 307: 674-684.
25. Lieben L, Carmeliet G., The delicate balance between vitamin D, calcium and bone homeostasis: Lessons learned from intestinal- and osteocyte-specific VDR null mice. J Steroid Biochem Mol Biol 2012.
26. Park JW, Cho JW, Joo SY, et al. Paricalcitol prevents cisplatin-induced renal injury by suppressing apoptosis and proliferation. Eur J Pharmacol 2012; 683: 301-309.
27. de Zeeuw D, Agarwal R, Amdahl M, et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): A randomised controlled trial. Lancet 2010; 376: 1543-1551.
28. Park JW, Bae EH, Kim IJ, et al. Paricalcitol attenuates cyclosporine-induced kidney injury in rats. Kidney Int 2010; 77: 1076-1085.
29. Saini RK, Kaneko I, Jurutka PW, Forster R, Hsieh A, Hsieh JC, Haussler MR, Whitfield GK., 1,25-dihydroxyvitamin d3 regulation of fibroblast growth factor-23 expression in bone cells: Evidence for primary and secondary mechanisms modulated by leptin and interleukin-6. Calcif Tissue Int 2013; 92: 339-353.
30. Park WD, Griffin MD, Cornell LD, Cosio FG, Stegall MD., Fibrosis with inflammation at one year predicts transplant functional decline. J Am Soc Nephrol 2010; 21: 1987-1997.